KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elanco Animal Health (ELAN) Accumulated Expenses (2017 - 2025)

Elanco Animal Health's Accumulated Expenses history spans 9 years, with the latest figure at $206.0 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 16.38% year-over-year to $206.0 million; the TTM value through Dec 2025 reached $206.0 million, up 16.38%, while the annual FY2025 figure was $206.0 million, 16.38% up from the prior year.
  • Accumulated Expenses for Q4 2025 was $206.0 million at Elanco Animal Health, up from $177.0 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $206.0 million in Q4 2025 and bottomed at $110.0 million in Q1 2023.
  • The 5-year median for Accumulated Expenses is $146.0 million (2022), against an average of $146.7 million.
  • The largest annual shift saw Accumulated Expenses soared 102.85% in 2021 before it fell 21.08% in 2022.
  • A 5-year view of Accumulated Expenses shows it stood at $185.0 million in 2021, then decreased by 21.08% to $146.0 million in 2022, then rose by 7.53% to $157.0 million in 2023, then grew by 12.74% to $177.0 million in 2024, then grew by 16.38% to $206.0 million in 2025.
  • Per Business Quant, the three most recent readings for ELAN's Accumulated Expenses are $206.0 million (Q4 2025), $177.0 million (Q4 2024), and $157.0 million (Q4 2023).